Free Trial
NASDAQ:ORIC

Oric Pharmaceuticals (ORIC) Stock Price, News & Analysis

Oric Pharmaceuticals logo
$11.73 -0.07 (-0.59%)
Closing price 04:00 PM Eastern
Extended Trading
$11.74 +0.00 (+0.04%)
As of 04:29 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Oric Pharmaceuticals Stock (NASDAQ:ORIC)

Key Stats

Today's Range
$11.53
$11.91
50-Day Range
$4.73
$11.80
52-Week Range
$3.90
$14.67
Volume
287,772 shs
Average Volume
757,734 shs
Market Capitalization
$999.63 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$18.57
Consensus Rating
Buy

Company Overview

Oric Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
86th Percentile Overall Score

ORIC MarketRank™: 

Oric Pharmaceuticals scored higher than 86% of companies evaluated by MarketBeat, and ranked 131st out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Oric Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Oric Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Oric Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Oric Pharmaceuticals are expected to grow in the coming year, from ($2.17) to ($1.96) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Oric Pharmaceuticals is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Oric Pharmaceuticals is -6.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Oric Pharmaceuticals has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Oric Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    15.84% of the float of Oric Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oric Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Oric Pharmaceuticals has recently decreased by 1.02%, indicating that investor sentiment is improving.
  • Dividend Yield

    Oric Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Oric Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    15.84% of the float of Oric Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Oric Pharmaceuticals has a short interest ratio ("days to cover") of 10.7, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Oric Pharmaceuticals has recently decreased by 1.02%, indicating that investor sentiment is improving.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Oric Pharmaceuticals this week, compared to 4 articles on an average week.
  • Search Interest

    Only 5 people have searched for ORIC on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Oric Pharmaceuticals insiders have sold 58.30% more of their company's stock than they have bought. Specifically, they have bought $262,976.00 in company stock and sold $416,289.00 in company stock.

  • Percentage Held by Insiders

    Only 6.82% of the stock of Oric Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    95.05% of the stock of Oric Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Oric Pharmaceuticals' insider trading history.
Receive ORIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oric Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ORIC Stock News Headlines

Bitcoin Beats Gold — But This Coin Could Beat Them Both
Bitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, who called Bitcoin’s breakout to $100K nearly to the day, says a lesser-known coin could be even bigger. It’s faster, cheaper, and backed by Google, Visa, and top VCs with over $200 million already invested.
See More Headlines

ORIC Stock Analysis - Frequently Asked Questions

Oric Pharmaceuticals' stock was trading at $8.07 on January 1st, 2025. Since then, ORIC shares have increased by 45.4% and is now trading at $11.73.

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) released its quarterly earnings data on Monday, May, 5th. The company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.51) by $0.09.

Oric Pharmaceuticals (ORIC) raised $75 million in an initial public offering (IPO) on Friday, April 24th 2020. The company issued 5,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Citigroup, Jefferies and Guggenheim Securities acted as the underwriters for the IPO.

Top institutional shareholders of Oric Pharmaceuticals include Palumbo Wealth Management LLC (0.05%). Insiders that own company stock include Jacob Chacko, Dominic Piscitelli, Pratik S Multani and Angie You.
View institutional ownership trends
.

Shares of ORIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Oric Pharmaceuticals investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), TotalEnergies (TTE), The RMR Group (RMR) and Southern First Bancshares (SFST).

Company Calendar

Last Earnings
5/05/2025
Today
7/24/2025
Next Earnings (Estimated)
8/11/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ORIC
CIK
1796280
Fax
N/A
Employees
80
Year Founded
N/A

Price Target and Rating

High Price Target
$22.00
Low Price Target
$12.00
Potential Upside/Downside
+60.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

EPS (Trailing Twelve Months)
($1.87)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$127.85 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-51.14%
Return on Assets
-46.29%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.00
Quick Ratio
12.00

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.45 per share
Price / Book
3.36

Miscellaneous

Outstanding Shares
85,220,000
Free Float
79,412,000
Market Cap
$986.51 million
Optionable
Optionable
Beta
1.54
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:ORIC) was last updated on 7/24/2025 by MarketBeat.com Staff
From Our Partners